Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Bortezomib in Refractory Multiple Myeloma
NCT00193557Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- May 2004
- Primary completion
- May 2006
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in multiple myeloma (MM), sponsored by SCRI Development Innovations. Primary endpoint: Objective Response Rate. Started May 2004; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00193557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193557.